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Objective: There is a critical need to establish genetic markers that explain the complex
phenotypes and pathogenicity of ALS. This study identified a polymorphism in the
Stathmin-2 gene and investigated its association with sporadic ALS (sALS) disease risk,
age-of onset and survival duration.
Methods: The candidate CA repeat was systematically analyzed using PCR, Sanger
sequencing and high throughput capillary separation for genotyping. Stathmin-2
expression was investigated using RT-PCR in patient olfactory neurosphere-derived
(ONS) cells and RNA sequencing in laser-captured spinal motor neurons.
Results: In a case-control analysis of a combined North American sALS cohort (n = 321)
and population control group (n = 332), long/long CA genotypes were significantly
associated with disease risk (p = 0.042), and most strongly when one allele was a 24 CA
repeat (p = 0.0023). In addition, longer CA allele length was associated with earlier age-
of-onset (p = 0.039), and shorter survival duration in bulbar-onset cases (p = 0.006). In
an Australian longitudinal sALS cohort (n = 67), ALS functional rating scale scores were
significantly lower in carriers of the long/long genotype (p = 0.034). Stathmin-2 mRNA
expression was reduced in sporadic patient ONS cells. Additionally, sALS patients and
controls exhibited variable expression of Stathmin-2 mRNA according to CA genotype
in laser-captured spinal motor neurons.
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Conclusions: We report a novel non-coding CA repeat in Stathmin-2 which is
associated with sALS disease risk and has disease modifying effects. The potential
value of this variant as a disease marker and tool for cohort enrichment in clinical trials
warrants further investigation.
Keywords: amyotrophic lateral sclerosis, genetic variant, genetic association studies, stathmin-2, genetic marker,
structural variation, motor neuron disease
INTRODUCTION
Stathmin-2 (encoded by STMN2), has recently been reported
as a potential contributor to the pathogenesis of ALS (Klim
et al., 2019; Melamed et al., 2019). STMN2, a member of the
stathmin family of proteins, encodes a phosphoprotein that has
an important role in microtubule dynamics (Cook and Petrucelli,
2019). Microtubules are essential in maintaining the integrity of
axonal signal transduction and cellular transport systems, as well
as being important in neuronal growth and cell division (Kapitein
and Hoogenraad, 2015). Core to the role of microtubules is
their “dynamic instability,” namely the ability to switch between
a state of rapid shrinkage and polymerization (Kapitein and
Hoogenraad, 2015), which is largely mediated by microtubule
associated proteins such as stathmin.
The Stathmin-2 protein promotes microtubule dynamics
in axonal growth cones (Riederer et al., 1997; Morii et al.,
2006), and is thought to play an important role in neurite
outgrowth (Stein et al., 1988). Following nerve crush injury,
Stathmin-2 is upregulated in the growth cones of regenerating
axons (Shin et al., 2014), with mutant STMN2 expression being
associated with retraction of motor neurons from innervated
neuromuscular junctions in Drosophila (Graf et al., 2011).
Additionally, neurite growth is impacted by STMN2 knockdown
in human motor neurons, and these cells fail to exhibit
extension compared to wild-type STMN2 cell lines (Klim
et al., 2019). Therefore, Stathmin-2 has been proposed as an
axonal maintenance factor that, when depleted, can accelerate
neurodegeneration, making this gene highly relevant in the
context of ALS (Klim et al., 2019; Melamed et al., 2019).
Stathmin-2 is highly regulated by the RNA splicing factor
TDP-43 (encoded by Transactive response DNA binding protein-
43 kDa, TARDBP) that forms hallmark neuronal protein
aggregates in both familial and sporadic ALS (sALS) (Nguyen
et al., 2018), and knockdown of TDP-43 was recently shown
to significantly reduce STMN2 transcript levels (Klim et al.,
2019; Melamed et al., 2019). TDP-43 plays a critical role in the
repression of non-conserved cryptic exons, thus when TDP-43
aggregation and loss of function occurs, it facilitates the inclusion
of a cryptic exon in the STMN2 transcript (Ling et al., 2015;
Melamed et al., 2019). Such conservation leads to the translation
of an early stop codon resulting in a non-functional protein (Klim
et al., 2019; Melamed et al., 2019). Reduced STMN2 expression
has been reported in spinal cord sections and human motor
neurons of ALS patients, and has been attributed to this early
polyadenylation mechanism (Klim et al., 2019; Melamed et al.,
2019).
In the current study, the CA repeat variant of STMN2
was initially identified in silico using a short structural variant
evaluation algorithm (Saul et al., 2016), and was investigated
using PCR, capillary separation and Sanger sequencing. A cross-
sectional case-control study based on differential CA allele
and genotype frequencies was performed in a combined North
American sALS cohort, to determine if repeat length and
allele/genotype frequencies are associated with disease risk, age
of symptom onset, and survival duration. In addition, effects of
CA genotypes on disease progression and cumulative survival
were investigated in a smaller longitudinal follow-up cohort
of Australian sALS patients. STMN2 expression studies were
carried out in olfactory neurosphere-derived (ONS) cells from
sALS patients and controls, and in laser-captured postmortem
spinal motor neurons, with accompanying RNA sequencing data
(Krach et al., 2018).
MATERIALS AND METHODS
Study Participants for Case-Control
Studies
A combined cohort of 321 Caucasian North American sALS
patients and 332 Caucasian North American healthy age-
matched controls were used in the study. DNA and clinical
information including age of onset, site of disease onset and
survival duration, were collected from 152 sALS patients at
the Duke ALS clinic in accordance with the Health Insurance
Portability and Accountability Act (Pro00040665/323682).
In addition, DNA samples from 169 sALS patients and
332 population control samples were obtained from the
NINDS Repository, Coriell Institute for Medical Research
(Camden, NJ, United States). Additionally, a longitudinal
follow-up cohort of 67 Australian Caucasian sALS patients was
obtained from the Sporadic ALS Australia (SALSA) project
(HREC–2016-187, RGS1471, University of Western Australia
RA/4/20/5308). DNA and clinical information, including age-
of-onset, site of onset and ALSFRS scores at follow-up visits
were collected for patients. All participants were diagnosed by
board-certified neurologists and met the revised El Escorial
World Federation of Neurology criteria for the diagnosis of ALS
(Brooks, 1994).
Polymerase Chain Reaction and
Confirmation of Allele Length
To amplify the microsatellite, primers were designed to bind
sequences on either side of the CA repeat with the forward primer
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located in exon 3 and the reverse primer located in intron 3
(sequences and cycling conditions are shown in Supplementary
Table 1). Endpoint PCR reactions were prepared to a final
volume of 10 µl, containing: 7.2 µl of dH2O (Baxter Healthcare,
Old Toongabbie, NSW, Australia), 2 µl of MyFi reaction
buffer (Bioline, Sydney, NSW, Australia), 0.05 µl of MyFi
DNA polymerase (Bioline, Sydney, NSW, Australia), 0.375 µl
of forward and reverse primer (Integrated DNA Technologies,
Coralville, IA, United States) at 200 ng/µl, and 10 ng of
DNA. PCR products were then fractionated on a 2% agarose
(w/v) gel (Scientifix Pty Ltd., Clayton, VIC, Australia) in 1×
TAE and stained with red safe nucleic acid stain (iNtRON
Biotechnology, Scientifix Pty Ltd., Clayton, VIC, Australia) prior
to imaging using the Bio-Rad ChemiDoc MP Imaging System.
In heterozygous cases, individual amplicons were purified by
band-stab, (Bjourson and Cooper, 1992) and Sanger sequenced
by the Australian Genome Research Facility (AGRF) (Perth
Australia). Analysis was conducted using Finch-TV software
(version 1.5.0; Geospiza Inc.).
High-Throughput Genotyping
Due to the variability of the repeat region, genotyping was
performed via capillary separation using fluorescent end labeled
primers, as a way to improve genotype resolution. PCR reactions
were carried out using the above protocol except for the inclusion
of a FAM-labeled forward primer. PCR products were sent
for capillary separation at the AGRF (Perth Australia). Results




Olfactory mucosa biopsies were collected from four male sALS
patients and four healthy, age-matched control participants. ONS
cells (ONS cells) were generated from each biopsy according
to our previously described protocols (Féron et al., 2013). All
procedures were performed with written consent from the
participants and with approval by the human ethics committee of
Northern Sydney Local Health District (Sydney, Australia) and
the Griffith University Human Ethics Committee (Queensland,
Australia). The ONS cells were cultured in DMEM/F12 (1:1)
containing 10% fetal bovine serum (v/v) and fixed using
previously described methods (Gorecki et al., 2019). ONS
cells were washed in PBS + 0.2% Triton X and blocked in
3% goat serum for 1 hr. Cells were incubated overnight at
4◦C with Nestin (1:100 Thermo Fisher Scientific, Waltham,
MA, United States, MA1-110), NeuN (1:500 Abcam, SYD, AU,
ab177487) and β-tubulin (1:1000 Abcam, SYD, AU, ab18207)
primary antibodies. Following washes, cells were incubated
at room temperature for 1 h with secondary antibodies
Alexa Fluor 488 (1:400, Bio-Rad, Hercules, CA, United States,
ab150077) and Alexa Fluor 568 (1:400, Bio-Rad, Hercules,
CA, United States, ab175701). Nuclei were stained with DAPI
0.5 µg/ml (Sigma-Aldrich, St. Louis, MO, United States) with
final images taken on a Cytation 5 cell imager (BioTek, Winooski,
VT, United States).
RT-PCR
RNA was extracted using TRIzol (Thermo Fisher Scientific,
Waltham, MA, United States) as per manufacturer’s instructions
and resuspended in 30 µl of dH2O (Baxter Healthcare, Old
Toongabbie, NSW, Australia). cDNA was synthesized using
the SuperScript IV system (Thermo Fisher Scientific, Waltham,
MA, United States) in 20 µl reactions as per manufacturer’s
instructions, using 10 µl of template RNA with a total of 500 ng.
Endpoint PCR reactions forGAPDH andTARDBP were prepared
according to the MyFi enzyme protocol described above, STMN2
reactions amplifying across exons 1–2 were prepared to a final
volume of 10 µl, according to the hot start Phusion polymerase
protocol (Thermo Fisher Scientific, Waltham, MA, United States)
(primer sequences and cycling conditions, Supplementary
Table 1). PCR products were fractionated on a 2% agarose (w/v)
gel (Scientifix Pty Ltd., Clayton, VIC, Australia) and stained with
red safe nucleic acid stain (iNtRON Biotechnology, Scientifix Pty
Ltd., Clayton, VIC, Australia) prior to imaging using the Bio-
Rad ChemiDoc MP Imaging System, followed by densitometry
using image J software (National Institutes of Health, Bethesda,
MD, United States).
Human Postmortem Tissue
Human postmortem tissue collections were approved by the
Institutional Review Board (Benaroya Research Institute, Seattle,
WA, United States IRB# 10058 and University of California San
Diego, San Diego, CA, United States IRB# 120056) and were
obtained using a short postmortem interval acquisition protocol
that followed HIPAA-compliant informed consent procedures.
All sALS patients from whom tissues were obtained met the
modified EI Escorial criteria for definite ALS (Brooks et al., 2000).
Age-matched control nervous system tissues were obtained
from hospice patients once life support was withdrawn. The
average postmortem interval was 3.5 h for controls and 4.6 h
for sALS patients. Detailed methods for tissue collection and
pathological screening have been described previously (Krach
et al., 2018). Laser-captured motor neurones were micro-
dissected from lumbar spinal cord sections and RNA was
collected and sent for RNA sequencing analysis as previously
reported (Rabin et al., 2010; Krach et al., 2018). DNA was
collected for STMN2 CA genotyping.
Statistics
Case-control binary genotype associations were assessed using a
Pearson’s Chi-squared test, while case-control logistic regression
was used to assess joint genotypic effects according to allele
size categories (long and short) based on previous rationales
(Roses et al., 2010; Mis et al., 2017; Sproviero et al., 2017).
General linear models were used for the prediction of age of onset
by genotype category. Within the SALSA longitudinal study,
patient clinical characteristics were assessed over time using
general linear mixed models (LMMs). Naïve LMMs were used to
assess whether patient clinical characteristics were significantly
associated with ALSFRS scores over time. Corrected LMMs were
constructed to assess the impact of STMN2 genotype group (L/L)
on ALSFRS, independently of covariates. Variables identified as
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FIGURE 1 | Identification and characterization of CA repeat polymorphism in STMN2. (A) Schematic of the STMN2 primary transcript and the location of the CA
repeat. (B) Sanger sequencing confirming size and variability of CA alleles. (C) Representation of STMN2 CA alleles from capillary separation genotyping assay. The
blue peaks depict the fluorescent signal intensity with the allele peaks to determine genotype indicated by the black star. (D) Predicted in silico pre-mRNA structure
for STMN2 reference sequence (NC_000008.11) generated from RNAfold Web server. The image depicts the predicted structure spanning from base pairs
(79636317–79643806) with the red box indicating the portion of the pre-mRNA containing the variable CA repeat.
being statistically significant were included in the multivariable
corrected LMMs. Residual plots were examined for all models
and no violations were noted. Survival times were assessed using
Kaplan-Meir analysis and Cox proportional hazards models.
A p value below 0.05 was considered significant. Analyses were
carried out in IBM SPSS Statistics version 25.0 (IBM Co.,
Armonk, NY, United States).
RESULTS
Identification of a Polymorphic Structural
Variant in STMN2
A structural variant evaluation algorithm (Saul et al., 2016),
was used to search for polymorphic variants within STMN2
that are likely to have significant biological effects contributing
to disease risk. Structural variants were scored according to
24 different properties, previously described (Saul et al., 2016)
and the candidate CA variant was selected from a short list
for further investigation. The identified intronic CA repeat
(Figure 1A) was investigated on public genomic databases NCBI
and ensemble genome browser NC_000008.11 and 8:79641629-
79641672, respectively, to see if the region had been previously
resolved. Sanger sequencing revealed polymorphic CA alleles
of different lengths (Figure 1B), suggesting that this candidate
region is likely to be a highly informative genetic marker.
Capillary fragment separation confirmed alleles ranged from 10
to 26 CA repeats (representative plots shown in Figure 1C).
A subset of 7,490 base pairs across the STMN2 gene (79636317–
79643806) was mapped on RNAfold Web server (Institute
for Theoretical Chemistry), to determine if the variable CA
repeat altered secondary pre-mRNA structure. The predicted
pre-mRNA structure was based upon the base pair sequence
entered into the RNAfold Web server, therefore the structural
prediction was the same for both cases and control with the same
number of CA repeats. Interestingly, when CA repeat length was
>18 CA, the repeat formed an open circular structure in the
predicted pre-mRNA that was not present for those with <18 CA
repeats (Figure 1D).
Distribution of Alleles and Genotypes in
North American sALS Cohorts
We next compared the distribution of the CA variant in the
152 Duke sALS cases, 169 Coriell sALS cases, and 332 healthy
control cases (cohort demographics Table 1). The distribution
of allele lengths ranged from 10 to 26 CA repeats in controls
and sALS cases, and tended to fall in two groups: those with
<19 CA repeats, classified as short alleles, and those ≥19 CA
repeats that were classified as long alleles. Both patient groups
consisted of individuals with self-reported Caucasian ethnicity
and there were no significant differences in allele distributions
between the Coriell and Duke cohorts (p> 0.8). Each distribution
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TABLE 1 | Demographics of study participants used for case-control association.
Duke cases (n = 152) Coriell cases (n = 169) Combined cohort (n = 321) Controls (n = 332)
Males 82 92 174 167
Age (years) 57.3 (12.1) 56.8 (12.6) 57.0 (12.4) 55.6 (16.9)
Females 70 77 147 165
Age (years) 57.8 (11.9) 60.4 (13.4) 58.0 (12.6) 57.7 (13.9)
Age of onset 57.5 (12.0) 55.8 (13.7) 56.6 (12.9) –
Disease duration (mths) 52.4 (38.1) – – –
Displayed as numbers of participants, means and standard deviations.
was compared to Webstr database and was similar to both
GTEx (predominantly European self-reported ancestry) and 1000
genomes European allele distributions, providing confidence
that the population in this study is reflective of a Caucasian
population of European descent. The two patient groups were
therefore combined to increase the sample size and power to
detect genetic effects.
Long STMN2 Alleles Are Associated With
Disease Risk in North American sALS
Cohorts
There was a significantly higher frequency of genotypes with two
long alleles (≥19 CA) in sALS cases compared to healthy controls
(Table 2). In contrast, there was a significantly higher frequency
of the long/short genotype in controls. At the individual allele
level, only the presence of a 24 CA repeats was significantly
associated with sALS cases, when it was part of a long/long
genotype (p = 0.041, OR = 1.75, CI = 1.05–2.90, Figure 2A).
To consider the impact of having two long alleles (≥19 CA)
with the presence or absence of a 24 CA repeat, a case-control
logistic regression was performed. In sALS cases there was a
significantly higher frequency of those carrying two long alleles
with at least one being the 24 CA repeat, whilst the frequency of
those carrying two long alleles but without a 24 CA allele did not
differ significantly between cases and controls. This effect was not
abrogated by correction for age or gender.
Long STMN2 Alleles Are Associated With
Earlier Age-of-Onset in North American
sALS Cohorts
To examine the effect of CA repeat length on age of disease onset,
a generalized linear model was used. Within cases, carriage of at
least one long allele (≥19 CA) was associated with a 7.5 years
lower age at onset compared to other genotypes (p = 0.039,
S/S = 63.85 years vs. other genotypes = 56.28 years; CI = 0.43–
14.7).
Long STMN2 Alleles Are Associated With
Reduced Survival in Bulbar-Onset
Patients
End-point survival data was available for 143 of the 152 patients
from the Duke University cohort. There was no significant
difference in the survival times for those carrying two long alleles
including 24 CA, and carriage of other genotypes (p = 0.6,
Figure 2B). However, when categorized according to site of
onset (bulbar vs. spinal), the bulbar cases carrying two long
alleles including 24 CA had significantly shorter survival times
than other bulbar cases (p = 0.0038, Hazard ratio [HR] = 3.2,
CI = 1.45–7.0). There was no significant difference between
survival times for bulbar cases not carrying the long alleles and
spinal cases with or without the long alleles (p = 0.54). Relative to
this latter combined group, bulbar cases carrying the long alleles,
including the 24 CA repeat, had significantly shorter survival
times (p = 0.006, HR = 3.4, CI = 1.6–7.1, Figure 2C). These
results were not abrogated by adjustment for gender and age
at disease onset.
Long STMN2 Alleles Are Associated With
Increased Disease Severity in an
Australian sALS Cohort
The relationship between STMN2 CA alleles and disease severity
and survival was also investigated in a cohort of 67 sALS
patients from the SALSA project, who were followed up over
periods of up to 25 months, with an average of 4 follow-
up time points per patient (cohort demographics and clinical
information are shown in Table 3). The frequency of CA
TABLE 2 | Distribution of CA genotypes in North American sALS and control cohorts.
Genotype sALS Controls p value OR 95% CI
Long/long (L/L) 203 (63.2%) 183 (55.1%) 0.042* 1.4 1.02–1.92
L/L (with a 24 CA) 37 (11.5%) 18 (5.4%) 0.0023**# 2.60 1.41–4.97
L/L (without 24 CA) 166 (51.7%) 165 (49.7%) 0.15# 1.27 0.92–1.76
Long/short (L/S) 105 (32.7%) 135 (40.7%) 0.035* 1.19 1.01–1.39
Short/short (S/S) 13 (4.0%) 14 (4.2%) 0.91 1.04 0.48–2.26
Bold values are statistically significant. Significance level is indicated by *. *p < 0.05, ** p ≤ 0.01. # p values from corrected model. OR, odds ratio; CI, confidence interval.
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FIGURE 2 | Investigation of STMN2 CA genotypes and their association with sALS disease risk and survival. (A) Allele distributions of the STMN2 CA repeat for 332
healthy controls and 321 sALS cases. The dotted line indicates the cut-off point between short and long CA alleles. Those <19 CA repeats are considered a short
allele and those ≥19 CA repeats are considered a long allele. Significance is indicated by the *, p < 0.05. (B) Cumulative survival for 143 sALS patients from Duke
University based on those that had L/L 24 CA genotypes compared to those without. (C) Cumulative survival based on site of disease onset (bulbar and spinal) and
the presence of the L/L 24 CA genotypes.
genotypes in this cohort was: S/S = 3, S/L = 23, L/L = 41.
With the limited number of participants in this cohort, sub-
group analysis incorporating the 24 CA allele was not possible.
To investigate the impact of STMN2 CA genotypes on ALSFRS
score over time, a generalized LMM was used which included
significant predictors of change in ALSFRS, with age-at-onset, age
at assessment, time between follow-up assessments, and site of
onset as covariates. When accounting for repeated measures, the
CA variant was significantly associated with mean ALSFRS scores
over time (p = 0.034), with an overall reduction of 2.37 ALSFRS
points in carriers of the L/L genotype (see Supplementary
Table 2, estimated means from the model were L/L 28.98 vs. other
genotypes 31.35). When the cumulative survival percentage was
analyzed using a Cox proportional hazards model, comparing
L/L genotypes to other genotypes, the L/L group showed a trend
toward decreased survival duration compared to those with at
least one short allele. Although not significant, the direction of
the trend was consistent with our previous observations (see
Supplementary Figure 1).
STMN2 Expression Is Reduced in sALS
Olfactory Neurosphere-Derived Cells
Compared to Controls
Previously, ONS cells have been used to model neurological
disorders (Matigian et al., 2010; Mackay-Sim, 2012). Given
the STMN2 CA repeat was associated with sALS disease risk,
age of onset and survival, we next asked whether the CA
repeat explained variability in STMN2 expression in control
and sALS age matched ONS cells lines (see Supplementary
Table 3). Immunostaining of primary ONS cells revealed
expression of Nestin, NeuN and β-tubulin, demonstrating
both progenitor/stem cells and mature neuronal characteristics
(Figure 3A). A distinct difference in STMN2 expression in
ONS cell lines was evident between healthy control and sALS
cases (Figures 3B,C). Within the control group, there was no
observable difference in STMN2 expression relative to CA repeat
length; however, expression was detected in only one of the four
sALS patient cell lines. No STMN2 expression was detected for
three of the patient cell lines, two of which had two long alleles
including one patient with the risk allele. There was no observable
difference in TARDBP expression between cases and controls
(Figures 3B,C).
Investigation of STMN2 CA Genotypes
and Expression in Postmortem
Laser-Captured Spinal Motor Neurons
Tissue samples and RNA sequencing analyses were conducted
on laser-captured motor neurons as previously reported (Krach
et al., 2018). Based on this data, we genotyped DNA from these
samples (see Supplementary Table 4), to examine if the CA
genotype could help to explain the large amount of variability
in STMN2 within sALS cases that was not directly related to the
presence of the cryptic exon, since all the patients were positive
for the truncated STMN2 transcript (Melamed et al., 2019). Once
samples were stratified by the CA genotype, a distinct trend was
observed in both patients and controls of decreasing STMN2
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expression between the S/L and L/L samples, however this did
not reach statistical significance (Figure 3D).
We next examined if the relative TDP pathology was different
between the CA genotypes of sALS patients (Figure 3E), when
standardizing phosphorylated TDP-43 positive motor neurons to
the number of morphologically intact motor neurons in laser-
captured samples, and found that there was no difference between
the percentages of motor neurons positive for phosphorylated
TDP between the two genotypes. Additionally, there was no
difference in the percentage of observed motor neuron death
between the S/L and L/L genotyped patients (Figure 3F).
DISCUSSION
This is the first report of a structural variant within STMN2
that is associated with sALS disease risk and also has disease-
modifying effects. In a combined North American sALS cohort,
the presence of at least one copy of the 24 CA repeat in genotypes
consisting of two long alleles was found to be significantly
associated with disease, thus confirming the hypothesis that
allele length is a determinant of disease risk. Intuitively, if
length is a driving factor, one could expect that carriage
of short alleles would be protective, and our data supports
this. In addition, the risk genotype group L/L (24 CA) was
associated with reduced survival when accounting for initial
site of disease onset and age at onset. Additionally, in a follow
up longitudinal Australian sALS cohort, there was a significant
reduction (2.3 points) in the mean ALSFRS score between the
L/L and other genotype group. These results suggest that the
CA variant may therefore be a potential marker to identify sub-
groups of sALS patients that progress in a particular way, and
could be a useful tool for cohort selection and enrichment in
clinical trials.
In silico modeling of the identified CA repeat suggests that it
has the potential to impact the binding of regulatory elements and
alter pre-mRNA structure. This was of particular interest because
it has previously been reported that hnRNP L (heterogeneous
nuclear ribonucleoprotein L) can act as an expression enhancer
and a regulator of splicing efficiency, with this function being
directly related to CA repeat length of the target mRNA (Hui
et al., 2003). Therefore, changes in CA repeat length could
influence hnRNP L binding to the target pre-mRNA and
potentially interfere with the binding of other regulatory elements
at nearby sites that initiate splicing and regulate gene expression.
To investigate effects on expression of STMN2, we measured
STMN2 mRNA in patient-derived ONS cells, taking into account
respective CA genotypes. Whereas STMN2 was detectable in all
control cell lines independent of CA repeat length, expression
was reduced in three of the four sALS cell lines investigated, in
keeping with the previous observation that STMN2 expression
is reduced in ALS motor neurons (Klim et al., 2019; Melamed
et al., 2019). Of particular note, two of the sALS cell lines with
no detectable STMN2 were found to carry longer versions of
the CA repeat, including the 24 CA risk allele. Interestingly, the
one sALS cell line that was positive for STMN2 expression also
shared a common 21 CA allele that was present in all four of
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FIGURE 3 | The effect of CA genotype on STMN2 mRNA expression in olfactory neurosphere derived cell lines and laser captured spinal motor neurons.
(A) Immunostaining of ONS cells with Nestin, NeuN, and β-tubulin. (B) Variable expression of STMN2 in sALS ONS cell lines (lanes 5–8) compared to control ONS
cell lines (lanes 1–4). (C) Relative densitometry of TARDBP and STMN2 standardized to GAPDH expression showing variable expression of STMN2 in sALS cell lines
and no difference in TARDBP. (D) Trend for a stepwise decrease in STMN2 mRNA expression between control and sALS cases according to STMN2 CA genotype
(S/L vs. L/L), error bars represent standard error of the mean. RNA sequencing data was analyzed by Krach et al. (2018) and STMN2 expression between cases and
controls previously reported (Melamed et al., 2019). (E) Percentage of motor neurons positive for phosphorylated TDP-43 during initial sample collection done by
Krach et al. (2018), according to STMN2 CA genotype. (F) Percentage of motor neuron death according to STMN2 CA genotype based on data collected by Krach
et al. (2018).
the control cell lines. Despite being a long allele, this suggests
that certain STMN2 alleles may exhibit increased expression,
and that the CA genotype may help to stratify differences in
basal STMN2 expression that are not accounted for by the TDP-
43 cryptic exon mechanism (Klim et al., 2019; Melamed et al.,
2019).
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To further investigate this notion, we next examined STMN2
CA genotypes in postmortem laser-captured motor neurons
for which accompanying RNA sequencing data was available
(Krach et al., 2018). It was reported previously that the average
expression of STMN2 was higher in controls compared to the
sALS patients, with the cryptic exon being present in all of
the sALS motor neurons (Melamed et al., 2019). However, this
alone did not explain the variability of STMN2 expression within
the patient group, or the degree of cryptic exon present, and
that the level of phosphorylated TDP-43 positive cells did not
always correlate with the level of full length STMN2 mRNA.
Although not definitive, the present results exhibit a trend for
a stepwise reduction in STMN2 expression between the S/L
and L/L genotypes, which was apparent both in control and
sALS motor neurons, suggesting that the CA genotype may
potentially reflect natural variability in the basal level of STMN2
transcription. The observed trend appeared to be independent of
the presence of phosphorylated TDP-43 in the collected motor
neurons, suggesting that this variant may tag fluctuations in gene
expression that cannot be identified purely by the level of cryptic
exon expression.
The recently elucidated regulation of STMN2 by the known
RNA splicing factor TDP-43 suggests that STMN2 may play a
critical role in ALS pathophysiology (Klim et al., 2019; Melamed
et al., 2019), particularly when TDP-43 pathology is present,
making it a strong candidate for therapeutic development (Cook
and Petrucelli, 2019). Since structural variants have the ability to
affect gene regulation (Cleary and Ranum, 2014, 2017; Rose et al.,
2016; Roses et al., 2016; Chiang et al., 2017), further expression
studies of the different STMN2 CA alleles are needed, particularly
with the presence of the 24 CA repeat. If the 24 CA repeat results
in reduced basal expression, this might further exacerbate disease
progression in patients with the TDP-43 mediated cryptic exon
mechanism (Ling et al., 2015), recently shown to play a significant
role in maintaining axonal outgrowth (Melamed et al., 2019).
Reduced STMN2 expression has been reported not only in iPSC
derived motor neurons in sALS and familial ALS cases with TDP-
43 pathology, but also in motor cortex and spinal motor neurons
of fALS and sALS patients with C9orf72 repeat expansions, the
most common inherited form of ALS (Melamed et al., 2019).
Additionally, reduced STMN2 expression has more recently been
reported in the brain of patients with Parkinson’s disease (Wang
et al., 2019), and frontotemporal dementia (Prudencio et al.,
2020). Further supporting the finding we present here, it was
also reported that levels of full length STMN2 were not always
correlated to phosphorylated TDP-43 burden in patients with
frontotemporal dementia (Prudencio et al., 2020), suggesting that
other factors outside the TDP-43/cryptic exon mechanism may
contribute to regulation of STMN2 expression.
Critical to understanding the implications of this data, is
to assess the landscape of known genetic markers for sALS.
Currently, there are only a few markers that explain increased
disease risk, age-of-onset distributions, and variability in disease
progression and survival (Blasco et al., 2011; Diekstra et al., 2012;
ALSGEN, 2013; Lopez-Lopez et al., 2014; Fogh et al., 2016; Van
Eijk et al., 2020; Yousefian-Jazi et al., 2020). Based on the data that
we have generated, identification of this marker is the first step
in fulfilling these requirements. As such, the STMN2 multiallelic
CA repeat is more informative than previously reported biallelic
single nucleotide polymorphisms (Landers et al., 2009; Blasco
et al., 2011; Diekstra et al., 2012; ALSGEN, 2013; Lopez-Lopez
et al., 2014; Fogh et al., 2016; Theunissen et al., 2020), and may
explain disease risk in a larger population of sALS patients. As a
critical neuronal maintenance factor (Shin et al., 2014; Klim et al.,
2019), attenuating STMN2 expression may be a viable therapeutic
approach to modify disease in a large proportion of both fALS
and sALS patients, and reinforces its potential development for
use as a prognostic marker or in clinical trials for ALS (Klim et al.,
2019; Melamed et al., 2019) and other neurodegenerative diseases
(Wang et al., 2019; Prudencio et al., 2020).
Importantly, we modeled the data using pre-determined long
and short allele cut-off lengths to increase the power to detect a
genetic effect, in a region that has a large number of genotypes.
As such, alleles were grouped into length categories according to
previous rationales (Roses et al., 2010; Mis et al., 2017; Sproviero
et al., 2017). Although a limitation of the study, this decision
was predicated on a clear distribution of alleles into two distinct
length categories. However, one must consider that by grouping
alleles, the frequency of long vs. short may change depending
on selection of cut-off points, and could result in changes in
individual allele frequencies. In order to accommodate this, we
initially interpreted the data with caution until it was clear that
the 24 CA allele (the longest allele at relatively high frequency)
enhanced the effect initially detected for the long allele group.
CONCLUSION
In conclusion, the STMN2 24 CA repeat, which was present
in 11.5% of sALS cases in our combined cohort, and
could potentially uncover disease risk in a significantly larger
proportion of sporadic patients than the few existing genetic
markers currently known for sALS. Moreover, the data that
we present adds weight to the recently elucidated regulatory
interactions between STMN2 and TDP-43 in the pathogenesis
of ALS. Such a discovery may work in parallel with the cryptic
exon mechanism in regulation of STMN2 expression and splicing
efficiency. Our data suggests that the STMN2 CA repeat may be
a potential sporadic disease marker for ALS that can be used as a
tool for cohort selection or to stratify variable patient response in
clinical trials.
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